# Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

> **NCT03885141** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Biolab Sanus Farmaceutica** · enrollment: 366 (estimated)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** Zolpidem

## Key facts

- **NCT ID:** NCT03885141
- **Lead sponsor:** Biolab Sanus Farmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 366 (ESTIMATED)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03885141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03885141, "Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03885141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*